2021 Annual Meeting | C3 - Assessment of Rapidly Progressive Dementias

Date Saturday 04/17/21

Time 09:00 AM - 10:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be familiar with the differential diagnosis of RPD and the clinical presentation and evaluation of the more common conditions.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Program Tracks Neurohospitalist, Advanced Practice Provider

Recommended Audience General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
09:00 AM - 09:35 AM EDT	Speaker	Approach to RPD: Prion Disease and Other (Non-autoimmune) RPDs Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
09:35 AM - 10:00 AM EDT	Speaker	Antibody Associated and Other Neuroinflammatory RPDs Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��

Faculty Disclosures
Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��	Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to �鶹��ýӳ�� interests or activities.